GT Medical Technologies, Inc. Secures $35 Million Venture Loan Facility from Horizon Technology Finance
GT Medical Technologies, Inc. has secured a $35 million venture loan facility from Horizon Technology Finance (NASDAQ: HRZN), with an initial funding of $15 million. The company plans to use the proceeds to execute strategic commercial and clinical expansion plans for GammaTile庐, their innovative targeted radiation solution for brain tumors. GammaTile is a bioresorbable collagen tile embedded with Cesium-131 seeds, delivering high-dose radiation directly to tumor cavities while minimizing damage to healthy tissue.
GT MedTech aims to improve access to care and expand GammaTile utilization for patients with high-grade gliomas, brain metastases, and aggressive meningiomas. The company is backed by notable investors, including MVM Partners and Glide Healthcare Partners, and plans to invest more resources into GammaTile's development and expand its commercial teams nationwide.
GT Medical Technologies, Inc. ha ottenuto un finanziamento da 35 milioni di dollari da Horizon Technology Finance (NASDAQ: HRZN), con un finanziamento iniziale di 15 milioni di dollari. L'azienda prevede di utilizzare i proventi per attuare piani di espansione commerciale e clinica strategici per GammaTile庐, la loro innovativa soluzione di radioterapia mirata per i tumori cerebrali. GammaTile 猫 una tegola di collagene bioassorbibile incorporata con semi di Cesio-131, che eroga radiazioni ad alta dose direttamente nelle cavit脿 tumorali riducendo al minimo i danni ai tessuti sani.
GT MedTech mira a migliorare l'accesso alle cure e ad ampliare l'utilizzo di GammaTile per i pazienti con gliomi ad alto grado, metastasi cerebrali e meningiomi aggressivi. L'azienda 猫 sostenuta da investitori di rilievo, tra cui MVM Partners e Glide Healthcare Partners, e prevede di investire maggiori risorse nello sviluppo di GammaTile e di espandere i suoi team commerciali a livello nazionale.
GT Medical Technologies, Inc. ha asegurado un pr茅stamo de riesgo de 35 millones de d贸lares de Horizon Technology Finance (NASDAQ: HRZN), con un financiamiento inicial de 15 millones de d贸lares. La empresa planea utilizar los fondos para ejecutar planes estrat茅gicos de expansi贸n comercial y cl铆nica para GammaTile庐, su innovadora soluci贸n de radiaci贸n dirigida para tumores cerebrales. GammaTile es un azulejo de col谩geno bioabsorvible incrustado con semillas de Cesio-131, que entrega radiaci贸n en alta dosis directamente a las cavidades tumorales, minimizando el da帽o al tejido sano.
GT MedTech tiene como objetivo mejorar el acceso a la atenci贸n y expandir la utilizaci贸n de GammaTile para pacientes con gliomas de alto grado, met谩stasis cerebrales y meningiomas agresivos. La empresa cuenta con el respaldo de inversores destacados, incluidos MVM Partners y Glide Healthcare Partners, y planea invertir m谩s recursos en el desarrollo de GammaTile y expandir sus equipos comerciales a nivel nacional.
GT Medical Technologies, Inc.電� Horizon Technology Finance(NASDAQ: HRZN)搿滊秬韯� 3,500毵� 雼煬鞚� 氩れ矘 雽�於� 鞁滌劋鞚� 頇曤炒頃橁碃, 齑堦赴 鞛愱笀鞙茧 1,500毵� 雼煬毳� 氚涭晿鞀惦媹雼�. 須岇偓電� 鞛愱笀鞚� 鞚挫毄頃橃棳 GammaTile庐鞚� 鞝勲灥鞝� 靸侅梾 氚� 鞛勳儊 頇曥灔 瓿勴殟鞚� 鞁ろ枆頃� 瓿勴殟鞛呺媹雼�. GammaTile電� 靹胳姌-131 鞌晽鞚� 靷届瀰霅� 靸濍秳頃挫劚 旖滊澕瓴� 韮�鞚�搿�, 瓯搓皶頃� 臁办鞐� 雽�頃� 靻愳儊鞚� 斓滌唽頇旐晿氅挫劀 膦呾枒 瓿惦彊鞐� 歆侅爲 瓿犾毄霟� 氚╈偓靹犾潉 鞝勲嫭頃╇媹雼�.
GT MedTech電� 瓿犽摫旮� 鞁犼步甑愳, 雵� 鞝勳澊 氚� 瓿店博鞝侅澑 靾橂膦� 頇橃瀽毳� 鞙勴暣 GammaTile鞚� 鞝戧芳靹膘潉 臧滌劆頃橁碃 頇滌毄霃勲ゼ 頇曥灔頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�. 須岇偓電� MVM Partners 氚� Glide Healthcare Partners鞕� 臧欖潃 鞝�氇呿暅 韴瀽鞛愲摛鞚� 歆�鞗愳潉 氚涭溂氅�, GammaTile鞚� 臧滊皽鞐� 雿� 毵庫潃 鞛愳洂鞚� 韴瀽頃橁碃 鞝勱淡鞝侅溂搿� 靸侅梾 韺�鞚� 頇曥灔頃� 瓿勴殟鞛呺媹雼�.
GT Medical Technologies, Inc. a obtenu un pr锚t d'amor莽age de 35 millions de dollars de Horizon Technology Finance (NASDAQ: HRZN), avec un financement initial de 15 millions de dollars. L'entreprise pr茅voit d'utiliser les fonds pour mettre en 艙uvre des plans d'expansion commerciale et clinique strat茅giques pour GammaTile庐, leur solution innovante de radioth茅rapie cibl茅e pour les tumeurs c茅r茅brales. GammaTile est un carreau de collag猫ne bio-r茅absorbable incorpor茅 de graines de c茅sium-131, d茅livrant des doses 茅lev茅es de radiations directement dans les cavit茅s tumorales tout en minimisant les dommages aux tissus sains.
GT MedTech vise 脿 am茅liorer l'acc猫s aux soins et 脿 茅tendre l'utilisation de GammaTile pour les patients atteints de gliomes de haut grade, de m茅tastases c茅r茅brales et de m茅ningiomes agressifs. L'entreprise est soutenue par des investisseurs notables, y compris MVM Partners et Glide Healthcare Partners, et pr茅voit d'investir davantage de ressources dans le d茅veloppement de GammaTile et d'茅largir ses 茅quipes commerciales 脿 l'茅chelle nationale.
GT Medical Technologies, Inc. hat ein Risikokreditvolumen von 35 Millionen Dollar von Horizon Technology Finance (NASDAQ: HRZN) gesichert, mit einer anf盲nglichen Finanzierung von 15 Millionen Dollar. Das Unternehmen plant, die Gelder zur Umsetzung von strategischen kommerziellen und klinischen Expansionspl盲nen f眉r GammaTile庐, ihre innovative gezielte Strahlentherapiel枚sung f眉r Gehirntumoren zu verwenden. GammaTile ist ein bioresorbierbarer Kollagenteil, das mit C盲sium-131-Quellen best眉ckt ist, das hochdosierte Strahlung direkt an Tumorkavit盲ten abgibt und gleichzeitig Sch盲den an gesundem Gewebe minimiert.
GT MedTech zielt darauf ab, den Zugang zur Versorgung zu verbessern und die Nutzung von GammaTile bei Patienten mit hochgradigen Gliomen, Gehirnmetastasen und aggressiven Meningeomen auszubauen. Das Unternehmen wird von namhaften Investoren unterst眉tzt, darunter MVM Partners und Glide Healthcare Partners, und plant, weitere Ressourcen in die Entwicklung von GammaTile zu investieren und seine Verkaufsteams landesweit zu erweitern.
- Secured $35 million venture loan facility from Horizon Technology Finance
- Initial funding of $15 million received
- Funds to be used for strategic commercial and clinical expansion of GammaTile
- GammaTile offers targeted radiation therapy, minimizing damage to healthy tissue
- Backed by top-tier investors including MVM Partners and Glide Healthcare Partners
- None.
Insights
GT Medical Technologies'
The company's ability to secure this funding, coupled with support from established investors like MVM Partners and Glide Healthcare Partners, indicates strong market confidence in their technology. This financial flexibility should accelerate GT MedTech's market penetration and potentially lead to increased revenue streams. However, investors should monitor how effectively the company utilizes this capital to drive growth and achieve profitability.
GammaTile's innovative approach to targeted radiation therapy represents a significant advancement in brain tumor treatment. By delivering high-dose radiation directly to the tumor cavity, it addresses key limitations of external beam radiation therapy, potentially improving patient outcomes and quality of life.
The expansion plans funded by this loan could accelerate clinical trials and real-world evidence gathering, important for wider adoption and potential inclusion in treatment guidelines. If successful, this could disrupt the current standard of care for high-grade gliomas, brain metastases and aggressive meningiomas. Investors should watch for upcoming clinical data and regulatory milestones, as these will be key indicators of GammaTile's long-term market potential and GT MedTech's growth trajectory.
The brain tumor treatment market is ripe for innovation and GT MedTech's GammaTile is well-positioned to capitalize on this opportunity. The
However, market adoption of new medical technologies can be slow, often requiring extensive education of healthcare providers and overcoming reimbursement hurdles. Investors should monitor GT MedTech's progress in expanding its market reach and securing favorable reimbursement policies. The company's success in these areas will be important in translating its innovative technology into sustainable financial performance and market share gains in the competitive oncology space.
The Company will use the loan proceeds to execute聽strategic commercial and clinical expansion plans for GammaTile庐. These initiatives will drive key corporate objectives that will support access to care, help patients diagnosed with high-grade gliomas, brain metastases, and aggressive meningiomas, and expand GammaTile utilization.
"We are delighted to have Horizon's support as we expand the reach of our innovative targeted radiation solution," said Per Langoe, Chief Executive Officer of GT MedTech. "Our partnership with Horizon Technology Finance will allow us to continue our strategic commercial and market expansion initiatives, helping bring GammaTile to more patients in need."
GammaTile is a bioresorbable collagen tile embedded with Cesium-131 seeds, a radioactive isotope that delivers a high dose of radiation directly to the tumor cavity, helping to reduce tumor recurrence. Unlike external beam radiation therapy, GammaTile uses surgically targeted radiation therapy that minimizes excess radiation exposure and potential damage to healthy tissue.
The Company is already backed by top-tier investors, including MVM Partners, Glide Healthcare Partners, MedTech Venture Partners and BlueStone Venture Partners.
"This partnership with Horizon allows us to continue to invest more of our resources into GammaTile and further the company's expansion within the brain tumor space," said Sandeep Yadav, Chief Financial Officer at GT MedTech. "We continue to be driven by the limitations of the current standard of care treatments and will use this funding to expand our commercial teams in order to reach more patients in need of this treatment throughout the country."
About GT Medical Technologies, Inc.
Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. GammaTile庐 is FDA-cleared as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. Since its full market release in
About Horizon Technology Finance
Horizon Technology Finance Corporation (NASDAQ: HRZN), externally managed by Horizon Technology Finance Management LLC, an affiliate of Monroe Capital, is a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio's return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations, beliefs, or projections. These forward-looking statements are based on management's current expectations and involve significant risks and uncertainties that may cause actual results, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements. Such factors and risks which could cause actual results to differ materially from those in the forward-looking statements include, without limitation: regulatory risks such as changing CMS, NRC, FDA rules and regulations impacting clearance and/or reimbursement of indicated products; supply chain disruptions; clinical trial and investigation risks including adverse patient outcomes such as death and other severe complications; cost of capital and inflationary risk of raw materials; legal and regulatory risks associated with potential mergers, acquisitions, investments in joint ventures; other global and regulatory uncertainties. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
Lori Kagan
GT Medical Technologies
lkagan@gtmedtech.com
(941) 224-6037
Dawn Fallon
New Dawn Communications
dfallon@newdawncomms.com
(732) 771-7808
View original content to download multimedia:
SOURCE GT Medical Technologies
FAQ
What is the value of the venture loan facility secured by GT Medical Technologies from Horizon Technology Finance (HRZN)?
What is GammaTile and how does it work in treating brain tumors?
How does GT Medical Technologies plan to use the funds from the HRZN loan?
Who are some of the investors backing GT Medical Technologies?
